EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 165 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... February 16, 2022 Empoderar a las personas con cáncer: preguntas y respuestas con la... June 8, 2021 Cancer and Climate Change: The Health Threats of Unnatural Disasters April 5, 2023 Finding Purpose During Cancer: A Survivor’s Story December 27, 2022 Load more HOT NEWS Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than... Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 From Scan to Scan: The Challenges of Living with Metastatic Cancer Breast Cancer Survivors Are Still Underrepresented At Victoria’s Secret
